

OTC Markets

Welcome to today's podcast. I'm your host, Stephen Shipley. Today, I'm pleased to be joined by Cheryl Maley, the CEO of Star Pharma Holdings Limited, an Australian biopharmaceutical company which trades in the OTC markets under the symbols SPHRF and SPHRY. Starpharma is an innovative company with two decades of experience in advancing dendrimer technology from the lab to the patient. Their mission is to help patients with significant illnesses such as cancer achieve improved health outcomes and quality of life through the application of their technology. In this conversation, we'll explore the origins of the company, how their platform differentiates itself in a competitive biotech landscape, recent clinical and corporate milestones, and how management is thinking about long-term value creation for their shareholders. It's a great opportunity to hear from the CEO about the strategy, the science, and what's next for Star Pharma. Let's get started. Cheryl, welcome to the OTC Markets podcast. It's great to have you on.

Cheryl Maley

Thanks so much, Stephen. It's great to be here.

OTC Markets

So, Cheryl, can you tell us about Star Pharma and provide an overview of the company's mission in the pharmaceutical space?

Cheryl Maley

Yeah, so Star Pharma has been around for over 20 years, and we came out of a research institute in Australia based on a proprietary dendrimer technology that helps with drug delivery. And our mission continues through history but also evolving now to really make sure that we build our dendrimer technology into the advancements and needs of patients that require new treatments and that have a huge unmet need. Our technology can be used quite broadly. And so, we focused on oncology, but our mission is really to make sure that we use our technology to improve patient outcomes.

OTC Markets

So, for investors unfamiliar with Dendrimers, how would you describe the debt platform in simple terms?

Cheryl Maley

So, the DEP platform or the Dendrimer itself is a spherical structure. It is very

precise and it's made from lysine, which is an amino acid. And basically, it's made of concentric layers of lysine. So, we continue to build on that to achieve different sizes. What we have on the surface layer of the dendrimer is also various branches, and depending on the size of the dendrimer would also impact the number of attachment points or branches on that dendrimer. As I said, they are very precise. So, our second-generation dendrimer has eight attachment points, and it goes all the way up to a but fifth generation, which has 64 attachment points. And you can attach various molecules to that layer of the dendrimer. And that gives it versatility. So, you could attach a targeting molecule all the way from a full antibody to a small molecule. You could attach a radio isotope. You can cover off attachment points that you're not using. And that is important that you decorate in a particular way and that you pick a particular size of dendrimer to get a particular outcome. So, the size and what you attach to it will influence the bio distribution of a drug. And that flows through to how efficacious the drug can be, the tolerability of a drug, ultimately what will be an outcome for a patient and the quality of life for a patient so it's very flexible but it's very precise

OTC Markets

And how does your platform aim to improve patient outcomes across therapies?

Cheryl Maley

Yeah so it really does come down to the selection of the size and what you attach or what we say decorate the dendrimer with because all of those variables will lead to a different outcome for the drug as to the way in which it will reach, you say, for example, in a particular cancer, the uptake in the tumor and avoiding various side effects will all be influenced by the way in which we structure that new dendrimer drug conjugate. That's the way in which we really focus on getting different outcomes. And we work with our partners and also for our internal assets that we're developing is that we try to look at what's available to patients at the moment or what's a challenge that's being focused in a new area of treatment and how could our dendrimer really benefit that. We know in various areas that there are drug limiting toxicities, you know, you can't get enough drug into the tumor because toxicities start to happen. So, attaching to a dendrimer can really help to make sure it's more focused to the tumor and not actually having those flow-on toxicities that may happen in some particular drug types. So that's where we really focus on and trying to work out what is that problem that exists today, what a patient's experience and how can our dendrimer really modify that drug to

make it better and to get better outcomes.

OTC Markets

So, moving from the science side, at a high level, what's Star Pharma's strategy for translating the debt platform into sustainable commercial and shareholder value?

Cheryl Maley

Yeah, I guess as a platform technology, there is always the ability to use it in many different ways. Our goal is to make sure that we look at areas, as I mentioned before, that have really high unmet need. And we do that by focusing on the assets that we're developing internally. So, we have commercial opportunity in licensing those assets to partners. And there's also the ability for us to license our technology to other companies for them to use it in their drug development programs. And we've got quite recent examples of that, where we have a joint venture with Medici, which is a private equity firm out of the UK and Europe. We have announced last year a licensing deal with Genetec, which are globally well known for their innovation and their ability to develop drugs, and they've licensed our technology. And then we have other partnerships that are research and development with the option to license. So, for Star Pharma, we have a focus on partnering and our internal asset development, which will ultimately lead to licensing those assets.

OTC Markets

So, moving on to the technology side of things, can you explain the core advantages of DEP in drug delivery compared to conventional methods?

Cheryl Maley

Yeah, and so and in some ways the dendrimer stands as quite unique to other options available, but in some ways, there are ways in which it can be complementary as well. So, you know, the dendrimer structure is something that can be used to enhance an existing drug or, as I mentioned, you know, that if there is a new drug in development to actually develop something that's quite unique and very focused on a better patient outcome. What differentiates Star Pharma dendrimer and the dendrimer enhanced products that we work on is one

is the technology and our experience of almost 25 years working with the technology and advancing it. We've also commercialized it. We have the depth of partner experience. And what we hear from our partners is one part of the value for Star Pharma is the technology, and the other is the depth of experience of our team. and the way in which we can use it and support somebody else using our technology. So, for me, that's really the power of Star Farma differentiation is that advancement in the technology, but the fact that we've commercialized it and also that we've got a team that has globally a unique experience.

OTC Markets

And are there specific drug classes where dendrimer technology provides the most impact?

Cheryl Maley

Yeah, I think it we're still exemplifying where it can be used. So, there's opportunities that we are continuing to advance. Where we have shown benefit primarily to date is in the oncology area. And that could range from, you know, quite broadly the chemotherapies that are used still today quite widely as backbone therapies, and then all the way through to targeted therapy. So, the work that we're doing in radiopharmaceuticals is exciting. We know that there is a lot of attention from a patient and clinician perspective, but also from a market perspective, there's a lot of interest in this radiopharmaceutical space. So the work we're doing is in part where we have our internal assets that we're developing and we're showing that the technology can address some of the challenges that have been shown in development for other companies there, which relate to high kidney retention and some toxicity if it's hanging around too long, either in the kidneys or the blood. And we've been able, you know, in our early work to show that dendrimers can bring benefit there. So that's in our asset that we're developing, but also, we're partnering in that space. We announced at the end of last year that we are working with Radio Farm, which is an Australian publicly listed radiopharmaceutical company. And so, your question is, you know how wide can we use it? I don't know that we've defined the full breadth of it yet, but our focus has been in oncology and now moving much more to targeted therapies.

OTC Markets

You just mentioned Radio Farm. So, Starpharma has multiple partnerships with

major pharma companies. Can you describe the nature of these collaborations?

Cheryl Maley

Yes, yeah. We have various ways in which we partner when we have experience over the years that we have been able to engage with different partnering models. Where we sit today, we have a joint venture with Medici, which we've created a single asset company called Battalion. We have 22.5% equity in that company. We have a licensing deal with Genetec, which is for a limited number of targets, and it is and enables them to use our technology in their drug development program for that limited number of targets. That total deal value was five and a half million US upfront and then around 550 million US in total value plus royalties. We also announced a research and development agreement at the end of last year, as I mentioned, with Radio Farm. That has an option for us to convert it to a single product focus. And the total deal value for that is around 55 million US plus royalties. So, it does vary, our partners. We also have launched a new program last year called Star Navigator. And that program allows potential partners to have an easier path to partnering with Star Pharma and an ability to work quite early to test if adding the dendrimer to their program or a specific program differentiates that product versus what they are working on today. And we're really excited about this program because it has created more opportunities for us to collaborate really fast and enable people to test the technology either in an existing program or a hypothesis. And so, we're excited that this could lead to many more partnerships for us going forward.

OTC Markets

It sounds like a nice way to fast track partnerships with the external companies out there.

Cheryl Maley

Yes.

OTC Markets

So how does the company prioritize investment across R&D? We mentioned partnerships and platform expansion.

Cheryl Maley

Yes, so we are very clear in our focus on that it is on selected assets that will be

important to patient outcomes in particular areas and commercial value to a potential partner if we license it. So that's from our, we dedicate resource to our internal asset development and then you know equal one is making sure that we have resourced our partnering programs to achieve their milestones either or exceed their expectations in the way in which we're working with them and collaborating. So, they're our top two priorities. We have products that are on market that we use for revenue generation to support Star Pharma. And that's what we call our focus on long-term sustainability. So, we have Viralese and VivaGel, which are available in multiple markets. They're registered in over 35 different countries. And we have partners that distribute and market those products, or we market them ourselves in some markets. And as I said that focus is a limited number of people within the organization, but it is focused purely on revenue that will support the business. Our top two priorities are our internal selected internal asset development and partnering, delivering or exceeding expectations for our partners.

OTC Markets

So, looking to the future, what upcoming milestones are you most excited about sharing with the investor community?

Cheryl Maley

Yeah, I think one of the most exciting ones for us is our radio program. And, you know, we have been working with companies and development in this space intensely for the last 18 months. And I'm excited to, you know, what we're seeing in some of the preclinical work. So, translating that through our clinical program is what I'm most excited about. And we aim to get our HER2 therapeutic, radiotherapeutic into clinic this year. So that would be a key milestone for us. Progress on our partners or licensing of assets would be another one. And expansion of partners, so bringing new partners into the business or indeed our existing partners expanding the utilization of our technology.

OTC Markets

And finally, for listeners who want to follow Starparma's progress, what resources or channels do you recommend?

Cheryl Maley

Yeah, I think there are multiple channels, but the way in which I would suggest that you become familiar with those multiple channels is if you go to the Star Farmer website, we have an Investor Hub section and most other of the channels

will also be listed through the Investor Hub or will provide a link to those other channels. So, Investor Hub within the Staff Farmer website will link you to various research articles, updates, our announcements, LinkedIn, and you know various other channels that you can get updates from.

OTC Markets

Well, thanks, Cheryl. It was great talking with you today, and we look forward to continuing to follow Starpharma's story and its future success.

Cheryl Maley

Thank you so much, Stephen I really appreciate your time today.

OTC Markets

And that wraps up another episode. My thanks to Cheryl Mailey for sharing her insights into Star Pharma's strategy, technology, and vision as the company continues to grow on the OTC markets. If you'd like to learn more about Star Pharma Holdings, which trades under the symbols SPHRF and SPHRY, be sure to check out their filings, updates, and company profile on the OTC markets website, as well as on Star Pharma's website. Thanks for listening and we'll catch you on the next episode.

**This is an autogenerated transcript and may contain typos.*